Global Quality Services-Analytical Sciences, Schering-Plough Corporation, Union, NJ 07083, USA.
J Pharm Biomed Anal. 2010 Jan 5;51(1):146-52. doi: 10.1016/j.jpba.2009.08.024. Epub 2009 Aug 26.
We reported the development of an ion-pair chromatographic method to separate desloratadine and all known related compounds in Clarinex Tablets, which use desloratadine as active pharmaceutical ingredient (API). For the first time, baseline separation for desloratadine and all known related compounds was achieved by utilizing a YMC-Pack Pro C(18) column (150 mm x 4.6 mm I.D., 3 microm particle size, 120A pore size) and a gradient elution method. The mobile phase A contains 3 mM sodium dodecylsulfate (SDS), 15 mM sodium citrate buffer at pH 6.2, and 40 mM sodium sulfate, while the mobile phase B is acetonitrile. Chromsword, an artificial intelligence method development tool, was used to optimize several key chromatographic parameters simultaneously including buffer pH/solvent strength, and temperature/gradient profile. The resolution of desloratadine and desloratadine 3,4-dehydropiperidine derivative, one of the critical pairs was improved by adding 40 mM sodium sulfate. Ultraviolet detection at 267 nm was used to achieve the detection for desloratadine and all compounds. This method has been successfully validated according to ICH guidelines in terms of linearity, accuracy, quantitation limit/detection limit, precision, specificity and robustness. It could be used as a stability indicating method for desloratadine drug substances or drug products that use desloratadine as active pharmaceutical ingredient.
我们开发了一种离子对色谱法,用于分离 Clarinex 片剂中的地氯雷他定和所有已知相关化合物,该片剂使用地氯雷他定为活性药物成分(API)。这是首次利用 YMC-Pack Pro C(18)柱(150mm×4.6mm ID,3μm 粒径,120A 孔径)和梯度洗脱方法实现地氯雷他定和所有已知相关化合物的基线分离。流动相 A 含有 3mM 十二烷基硫酸钠(SDS)、15mM 柠檬酸钠缓冲液(pH6.2)和 40mM 硫酸钠,而流动相 B 是乙腈。Chromsword 是一种人工智能方法开发工具,用于同时优化几个关键的色谱参数,包括缓冲液 pH/溶剂强度和温度/梯度曲线。通过添加 40mM 硫酸钠,提高了地氯雷他定和地氯雷他定 3,4-脱水哌啶衍生物(关键对之一)的分辨率。采用 267nm 紫外检测实现了对地氯雷他定和所有化合物的检测。该方法已根据 ICH 指南成功验证了线性、准确性、定量限/检测限、精密度、特异性和稳健性。它可用于作为地氯雷他定原料药或使用地氯雷他定为活性药物成分的药物产品的稳定性指示方法。